Cyclopharm (ASX:CYC) secured a five-year federal supply schedule agreement with the US Veterans Health Administration, expanding Technegas' adoption within the federal healthcare system, according to a Friday filing with the Australian bourse.
Technegas is a radioactive carbon dispersion used in ventilation-perfusion scans to diagnose lung conditions, including pulmonary embolism.
The deal streamlines procurement processes for US federal agencies, including the Veterans Administration (VA), Department of Defense, and Public Health Service hospitals by eliminating individual contracts across VA's 20 regional procurement offices, the filing said.
Shares rose nearly 4% in afternoon trade Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.